#niraparib

[hardoctornews]

Inibitori PARP: un nuovo standard di cura per il carcinoma ovarico epiteliale (EOC) avanzato di nuova diagnosi

I risultati degli studi di fase III condotti sui PARP inibitori (inibitori della poli (ADP-ribosio) polimerasi) nelle pazienti affette da carcinoma ovarico epiteliale mostrano la sostanziale efficacia di questi farmaci e comportano importanti implicazioni per la pratica clinica attuale e per la ricerca futura. In una review pubblicata di recente dalla rivista Cancers, un gruppo internazionale di…

View On WordPress

[ptmasterguide]

Niraparib (Mechanism of Action)

Niraparib (Mechanism of Action)

In this article, we will discuss Niraparib (Mechanism of Action). So, let’s get started. Mechanism of Action Niraparib is an inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, PARP-1 and PARP-2, which play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity mayinvolve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes…

View On WordPress

[ptmasterguide]

Niraparib

In this article, we will discuss Niraparib (Dosage Overview). So, let’s get started. Indications Niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Dosage Recommended Dosage The recommended dose of Niraparib as…

View On WordPress

[pushingarrows]

Niraparib - an inhibitor of PARP for the treatment of ovarian cancer.

[lucadezzani]

FDA Approves Tesaro’s niraparib for ovarian cancer March 27, 2017

[amcrasto]

Niraparib; MK 4827

MK-4827,(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxaMide Niraparib; MK 4827; MK4827 UNII:HMC2H89N35 1038915-60-4 CASfree form 1038915-64-8 CAS HYDROCHLORIDE 1613220-15-7 cas TOSYLATE MONOHYDRATE 1038915-73-9  TOSYLATE MK-4827(Niraparib) tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM; with great activity in cancer cells with mutant BRCA-1 and BRCA-2;…

View On WordPress

[bidhuan]

Uji Klinik NIRAPARIB Signifikan Tingkatkan Angka Hidup Penderita Kanker Ovarium

Uji Klinik NIRAPARIB Signifikan Tingkatkan Angka Hidup Penderita Kanker Ovarium

Majalah Farmasetika (Ed.5 – Juli 2016). Massachusetts. TESARO, Inc, sebuah perusahaan biofarmasi yang berfokus pada onkologi, pada tanggal 29 Juni 2016 mengumumkan bahwa uji klinik tahap 3 NOVA niraparib berhasil mencapai titik akhir utama dari peningkatan kelangsungan hidup (progression-free survival/PFS).

Studi ini menunjukkan obat percobaan secara signifikan menunjukan waktu PFS lebih lama…

View On WordPress